# BHR Partners

> BHR Partners is a VC fund in Beijing backing Hardware, Health Care and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 3
- Last investment: Jul 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/en.bhrpe.com/about/
- Website: http://www.bhrpe.com/

BHR Partners is a VC fund in Beijing focused on Hardware and Health Care. BHR Partners is the cross-border investment arm of Bohai Industrial Investment Fund.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Hardware | 1 | 33% |
| Health Care | 1 | 33% |
| Biotechnology | 1 | 33% |
| Semiconductor | 1 | 33% |
| Pharmaceutical | 1 | 33% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 1 | 33% |
| Hong Kong | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CYGNUSEMI | Cygnus Semi is a semiconductor chip technology company that focuses on 5G IoT applications. |  | Venture - Series Unknown | Jul 14, 2026 |  |
| Insilico Medicine | Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and,unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. | $35M | Series D | Aug 10, 2022 |  |
| Insilico Medicine | Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and,unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. | $60M | Series D | Jun 06, 2022 |  |

3 of 3 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 4 deals together
- [B Capital](https://shizune.co/investors/profile/b-capital-group) — VC Fund, 2 deals together
- [Bold Capital Partners](https://shizune.co/investors/profile/bold-capital) — VC Fund, 2 deals together
- [Deerfield](https://shizune.co/investors/profile/deerfield) — VC Fund, 2 deals together
- [Pavilion Capital](https://shizune.co/investors/profile/pavilion-capital) — VC Fund, 2 deals together
- [Pavilion Capital](https://shizune.co/investors/profile/pavilion-capital-57b7) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does BHR Partners invest in?

BHR Partners invests primarily in Hardware, Health Care and Biotechnology startups, most often at Series D and Venture - Series Unknown stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did BHR Partners last invest?

The most recent investment recorded for BHR Partners closed in Jul 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co